DUB3 promotes BET inhibitor resistance and cancer progression through deubiquitinating BRD4

The bromodomain and extra-terminal domain (BET) protein BRD4 is emerging as a promising anticancer therapeutic target. However, resistance to BET inhibitors often occurs and it has been linked to aberrant degradation of BRD4 protein in cancer. Here, we demonstrate that the deubiquitinase DUB3 binds...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cell
Autori principali: Jin, Xin, Yan, Yuqian, Wang, Dejie, Ding, Donglin, Ma, Tao, Ye, Zhenqing, Jimenez, Rafael, Wang, Liguo, Wu, Heshui, Huang, Haojie
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6086352/
https://ncbi.nlm.nih.gov/pubmed/30057199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molcel.2018.06.036
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi